Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) – Investment analysts at Jefferies Financial Group increased their Q2 2022 earnings per share estimates for Vertex Pharmaceuticals in a research note issued on Sunday, April 17th. Jefferies Financial Group analyst M. Yee now anticipates that the pharmaceutical company will post earnings per share of $3.24 for the quarter, up from their previous estimate of $3.22. Jefferies Financial Group also issued estimates for Vertex Pharmaceuticals’ FY2022 earnings at $12.67 EPS and FY2023 earnings at $13.27 EPS.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its earnings results on Wednesday, January 26th. The pharmaceutical company reported $3.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.27. Vertex Pharmaceuticals had a net margin of 30.92% and a return on equity of 32.33%. The company had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $1.99 billion. During the same quarter in the previous year, the company posted $2.22 earnings per share.
VRTX stock opened at $282.99 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.46 and a quick ratio of 4.30. The company has a 50 day moving average price of $250.14 and a 200 day moving average price of $221.46. Vertex Pharmaceuticals has a fifty-two week low of $176.36 and a fifty-two week high of $292.75. The stock has a market capitalization of $72.31 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 1.46 and a beta of 0.62.
In related news, Director Margaret G. Mcglynn sold 5,000 shares of the company’s stock in a transaction on Friday, January 28th. The shares were sold at an average price of $241.79, for a total value of $1,208,950.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Bastiano Sanna sold 1,040 shares of the company’s stock in a transaction on Wednesday, February 2nd. The stock was sold at an average price of $250.98, for a total transaction of $261,019.20. The disclosure for this sale can be found here. Insiders sold a total of 50,623 shares of company stock valued at $13,527,514 in the last three months. 0.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Concord Wealth Partners lifted its position in Vertex Pharmaceuticals by 750.0% during the 4th quarter. Concord Wealth Partners now owns 119 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 105 shares in the last quarter. First PREMIER Bank bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $27,000. Hudock Inc. lifted its position in Vertex Pharmaceuticals by 156.3% during the 3rd quarter. Hudock Inc. now owns 164 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 100 shares in the last quarter. Moors & Cabot Inc. bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $29,000. Finally, JJJ Advisors Inc. lifted its position in Vertex Pharmaceuticals by 101.5% during the 4th quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 67 shares in the last quarter. 90.30% of the stock is owned by hedge funds and other institutional investors.
Vertex Pharmaceuticals Company Profile (Get Rating)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.